Contrast Protalix's R&D efforts to Alexion which is hugely profitable and growing through expanded uses for its main drug Soliris. BioMarin is developing therapies for novel orphan disease with multiple, significant clinical trial catalysts later this year.
Protalix does have a unique technology platform in which plant cells are engineered to produce therapeutic proteins. Perhaps a larger company (Pfizer?) could do a better job unlocking the value there.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein.
>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.>To submit a news tip, send an email to: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.